⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Symbio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Symbio
↗Port Jefferson, NY, USA
Symbio is a global, full-service Clinical Research Organization (CRO) specializing in dermatology, aesthetics, gastroenterology, and inflammatory diseases. The company provides comprehensive clinical trial management, biometrics, strategic consulting, and topical formulation development services, supporting drug development and medical device studies from Phase I through Phase IV.
In 2023, Symbio merged with Proinnovera to form a leading dermatology-focused CRO, enhancing its global footprint and service capabilities across the US and Europe. The company is known for its client-focused approach, leveraging deep therapeutic expertise and long-standing site relationships to streamline recruitment and ensure regulatory-caliber data.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$50M-$100M
Founded:2002
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Service Provider)
Modalities:Small molecule, Topical formulations
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Proinnovera (merged entity), Dow Development Laboratories (merged entity), Saint Anthony Memorial Hospital (Phase I Unit collaboration)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Shanna Smith - President
Alan Morgan - Executive Chairman
Jon Mishkin - Chief Financial Officer
Tom McGuire - Chief Technology Officer
Scientific Founders:Richard Panico, Debra Dow
Board Members:Alan Morgan, Debra Dow, Patrick Ronan
LINKS
Website:symbioresearch.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Symbio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.